Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Association between Anti-Ro52/TRIM21 antibodies and disease severity (range, 0 to 4)

From: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis

  Whole group
(N = 963)
Anti-Ro52/TRIM21 antibody positive (n= 194) Anti-Ro52/TRIM21 antibody negative (n= 769) Odds ratio (95% CI) and Pvalues (Anti-Ro52/TRIM21 positive vs negative)
  Mean SD Mean SD Mean SD   
General 0.89 1.22 1.16 1.41 0.82 1.16 1.23 (1.09, 1.39) 0.0061
Skin 1.25 0.68 1.23 0.60 1.25 0.69 NS  
Kidney 0.12 0.61 0.12 0.61 0.12 0.61 NS  
Peripheral vascular 1.54 1.25 1.58 1.26 1.53 1.24 NS  
Joint/tendon 0.73 1.19 0.73 1.22 0.73 1.18 NS  
Muscle 0.25 0.74 0.33 0.89 0.22 0.70 NS  
Gastrointestinal 1.95 0.82 2.01 0.78 1.93 0.82 NS  
Lung 1.38 1.11 1.56 1.08 1.34 1.12 1.19 (1.04, 1.37) 0.0084
Heart 0.50 1.00 0.60 1.12 0.48 0.97 NS  
Physician global assessments of severity (range, 0-10) 2.77 2.26 2.99 2.31 2.71 2.24 NS  
Patient global assessments of severity (range, 0-10) 3.64 2.61 3.66 2.67 3.63 2.60 NS  
  1. CI, confidence interval; NS, not significant; SD, standard deviation.